Skip to main content
Full access
Editorials
Published Online: 1 November 2024

Higher Prevalence Estimates of Substance Use Disorders With DSM-5 Versus DSM-IV Criteria Among U.S. Nonelderly Adults With Substance Use: The Role of DSM-IV Diagnostic Orphans

Publication: American Journal of Psychiatry
In this issue of the Journal, Compton and colleagues have investigated an important issue, namely, whether national rates of past-year adult substance use disorders (SUD) were higher using DSM-IV or DSM-5 criteria, and if so, what changes in DSM-5 criteria accounted for the differences (1). A particular focus was whether the addition of a new criterion, craving, to DSM-5 was responsible for the increased rates. The Compton et al. study has many strengths. The significance of understanding differences in U.S. national prevalences of SUD using DSM-IV or DSM-5 criteria was made clear. The sample of 18–64-year old household residents was large and nationally representative. Four substances (alcohol, cannabis, cocaine and misused prescription opioids) were included. The year of the data collection (2021) enabled a much more recent look at the issue than several earlier studies that showed little difference in rates between DSM-IV and DSM-5 criteria (2).
Compton and colleagues found that prevalences of alcohol, cannabis, prescription opioids, and cocaine-related SUDs were 1.6–2.6 times higher with DSM-5 criteria than with DSM-IV criteria (DSM-IV abuse or DSM-IV dependence). Removing craving from the DSM-5 criteria set while keeping the same diagnostic thresholds reduced the differences in rates between DSM-IV and DSM-5. However, prevalence estimates of DSM-5 alcohol, cannabis, prescription opioids, and cocaine-related SUDs remained 1.3–2.1 times higher than corresponding DSM-IV SUD prevalence. Therefore, the addition of craving to the DSM-5 SUD criteria contributed to the differences in rates but did not explain the differences entirely. Compton and colleagues also found that omitting the craving criterion from the DSM-5 SUD criteria set resulted in loss of many mild DSM-5 SUD cases but very few moderate to severe ones. The authors concluded that relative to DSM-IV, DSM-5 detects mild cases that might benefit from prevention and early intervention.
Many earlier studies comparing within-subject diagnostic results using different nomenclatures calculated the level of within-participant agreement (kappa) on the diagnoses, including studies of DSM-IV and DSM-5 SUD (35). We therefore computed the kappas (chance-corrected agreement) for DSM-IV and DSM-5 SUD diagnoses in the 2021 NSDUH public use data set within the same age range as Compton et al. As shown in Table 1, agreement between DSM-IV and DSM-5 SUD diagnoses ranged from fair to excellent. Agreement between DSM-IV and DSM-5 SUD diagnoses was poorest with the DSM-5 threshold of 2+ criteria, which includes the mild as well as moderate and severe DSM-5 cases. Agreement between DSM-IV and DSM-5 SUD diagnoses was best across all four substances with the DSM-5 threshold of 4+, which excludes the mild cases. This suggests that cases that were mild in DSM-5 (two or three criteria) did not receive a SUD diagnosis when using DSM-IV criteria, consistent with the findings of Compton et al.
TABLE 1. DSM-IV and DSM-5 substance use disorders, prevalence and agreement by number of criteria in DSM-5
Substance (N of users)Prevalencea of DSM-IV SUDPrevalencea of DSM-5 SUDAgreement of DSM-IV SUD with DSM-5b
Threshold: 2+ criteriaThreshold: 3+ criteriaThreshold: 4+ criteria2+ criteria threshold3+ criteria threshold4+ criteria threshold
%SE%SE%SE%SEKappa95% CIKappa95% CIKappa95% CI
Alcohol (N=29,723)10.460.3318.710.4811.700.378.020.310.620.60–0.650.860.83–0.890.860.83–0.88
Cannabis (N=11,026)12.000.6231.100.9619.610.8112.970.700.460.42–0.500.690.65–0.730.790.75–0.82
Prescription opioids (N=1,464)13.841.6722.111.9715.001.5713.401.580.720.64–0.810.920.88–0.970.930.89–0.97
Cocaine (N=1,072)17.962.7927.983.1520.952.9715.792.820.710.61–0.810.890.80–0.980.910.83–0.98
a
Data from the 2021 National Survey on Drug Use and Health among US adults aged 18–64 who had specific substance use in the past 12 months, 12-month prevalence estimates of corresponding past 12-month substance use disorder; weighted percentage and standard errors account for complex sampling design.
b
The simple kappa coefficient and its 95% confidence intervals were estimated using a bootstrap variance estimation method (SAS PROC SURVEYFREQ).
To better understand the SUD cases that were missed by DSM-IV, we went back to the reasons for the changes between DSM-IV and DSM-5. A major change was to move from a two-disorder framework in DSM-IV (abuse and dependence) to a single-disorder framework in DSM-5. One of the main reasons for this change was that in DSM-IV, individuals could have one or two dependence criteria but no abuse criteria and therefore no SUD diagnosis. These individuals were termed “diagnostic orphans” (68), a term indicating no DSM-IV diagnosis among symptomatic individuals. Previously, diagnostic orphans accounted for much of the discrepancy when DSM-5 SUD rates were higher than DSM-IV, including samples from large genetics studies (4), clinical settings (5), primary care patients in the Veterans Administration (9), and adolescents (3). Because the DSM-5 rates remained 1.3–2.1 times higher in the Compton et al. study even after craving was removed from the criteria set, we explored whether diagnostic orphans (symptomatic individuals with no DSM-IV SUD diagnosis) accounted for the remaining discrepancies in rates between DSM-IV and DSM-5 SUD. Accordingly, among NSDUH 2021 participants ages 18–64, we identified the cases of DSM-5 alcohol, cannabis, cocaine, and prescription opioid use disorders that were undiagnosed in DSM-IV and found the following.
For alcohol use disorders (AUD), 1,559 participants were positive for DSM-5 AUD and negative for DSM-IV AUD, all of whom endorsed exactly two DSM-IV dependence criteria and thus were diagnostic orphans in DSM-IV. Of these, 56.3% had exactly two DSM-5 AUD criteria, and the rest had two DSM-5 AUD criteria plus craving.
For cannabis use disorders (CUD), 1,278 participants were positive for DSM-5 CUD and negative for DSM-IV CUD. Of these, 1,148 (89.8%) had exactly two DSM-IV dependence criteria and 130 (10.2%) endorsed one dependence criterion, and thus were diagnostic orphans in DSM-IV. Additionally, of the 130 participants with one DSM-IV dependence criterion, all endorsed cannabis withdrawal (not included in DSM-IV as a cannabis dependence symptom but added in DSM-5), and 85 of these (65.4%) additionally endorsed craving (also not present in DSM-IV and added in DSM-5). Thus, DSM-IV CUD criteria missed a substantial number of participants who were positive for CUD using DSM-5 criteria
For prescription opioid use disorders (POUD), 77 participants were positive for DSM-5 POUD and negative for DSM-IV POUD. All 77 endorsed two DSM-IV dependence criteria and thus were diagnostic orphans in DSM-IV.
For cocaine use disorders (CoUD), 38 participants were positive for DSM-5 CoUD and negative for DSM-IV CoUD, i.e., no DSM-IV CoUD. All 38 endorsed two DSM-IV dependence criteria and thus were diagnostic orphans in DSM-IV.
These findings for AUD, CUD, POUD, and CoUD indicate that the DSM-5 transition to a single-disorder SUD framework of graded severity accomplished an important goal, namely, providing a way to diagnose SUDs among individuals who were symptomatic but undiagnosed “orphans” in DSM-IV. By capturing these individuals diagnostically, DSM-5 rates were increased and the remaining discrepancies between DSM-IV and DSM-5 SUD rates not accounted for by the addition of the craving criterion were explained.
Several future directions are possible for this area of research. First, participants older than 65 years of age were omitted from all analyses. While this is an age group with historically low rates of substance use, these rates have recently been increasing. Therefore, comparisons of DSM-IV and DSM-5 SUD rates in older adults are needed, especially since SUD poses additional risks in older adults (e.g., falls, adverse interactions with medications for medical problems). Further information on discrepancies in rates is also needed by sex, race/ethnicity, by psychiatric comorbidity and by comorbidity with chronic pain, which can complicate the diagnosis of substance use disorders (10).

References

1.
Compton WM, Einstein EB, Han B: 12-month prevalence estimates of substance use disorders using DSM-5 versus DSM-IV criteria among U.S. nonelderly adults with substance use. Am J Psychiatry 2024; 181:1018–1021
2.
Hasin DS, O’Brien CP, Auriacombe M, et al: DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatry 2013; 170:834–851
3.
Kelly SM, Gryczynski J, Mitchell SG, et al: Concordance between DSM-5 and DSM-IV nicotine, alcohol, and cannabis use disorder diagnoses among pediatric patients. Drug Alcohol Depend 2014; 140:213–216
4.
Peer K, Rennert L, Lynch KG, et al: Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend 2013; 127:215–219
5.
Livne O, Shmulewitz D, Stohl M, et al: Agreement between DSM-5 and DSM-IV measures of substance use disorders in a sample of adult substance users. Drug Alcohol Depend 2021; 227:108958
6.
Hasin D, Paykin A: Dependence symptoms but no diagnosis: diagnostic “orphans” in a 1992 national sample. Drug Alcohol Depend 1999; 53:215–222
7.
Hasin D, Paykin A: Dependence symptoms but no diagnosis: diagnostic “orphans” in a community sample. Drug Alcohol Depend 1998; 50:19–26
8.
Pollock NK, Martin CS: Diagnostic orphans: adolescents with alcohol symptom who do not qualify for DSM-IV abuse or dependence diagnoses. Am J Psychiatry 1999; 156:897–901
9.
Takahashi T, Lapham G, Chavez LJ, et al: Comparison of DSM-IV and DSM-5 criteria for alcohol use disorders in VA primary care patients with frequent heavy drinking enrolled in a trial. Addict Sci Clin Pract 2017; 12:17
10.
Hasin DS, Shmulewitz D, Stohl M, et al: Diagnosing prescription opioid use disorder in patients using prescribed opioids for chronic pain. Am J Psychiatry 2022; 179:715–725

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 955 - 957

History

Accepted: 11 September 2024
Published online: 1 November 2024
Published in print: November 01, 2024

Keywords

  1. Substance Use
  2. Substance Use Disorder
  3. DSM-5
  4. DSM-IV
  5. Epidemiology

Authors

Details

Department of Psychiatry, Columbia University Medical Center (Hasin); New York State Psychiatric Institute, New York (Hasin, Stohl).
Malka Stohl, M.S.
Department of Psychiatry, Columbia University Medical Center (Hasin); New York State Psychiatric Institute, New York (Hasin, Stohl).

Notes

Send correspondence to Dr. Hasin ([email protected]).

Competing Interests

Dr. Hasin receives funding from Syneos Health for an unrelated project, i.e., provision of support services to U.S. Food and Drug Administration postmarketing requirement study 3033-1 on the prevalence and incidence of misuse, abuse and addiction to prescription opioid analgesics. Ms. Stohl reports no potential conflicts of interest.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share